File illustration of the file for vials with “Vaccine” written in front of the AstraZeneca logo, taken on September 9, 2020. Reuters / Dado Rovich / Clarification / Archive
AstraZeneca Laboratory may have included “old” data in its clinical trials in the US on a vaccine against covid-19.The US Medicines Regulatory Authority, citing a group of independent experts, said.
The group expressed “concern that AstraZeneca may have included outdated information in this trial, which may have led to an incomplete estimate of the effectiveness of the vaccine,” noted National Institute of Allergy and Infectious Diseases (Niede) in a statement issued Monday evening.
“We urge the laboratory to work with the DSMB (the Data and Safety Monitoring Board, a group of independent experts tasked with overseeing clinical trials, ndlr) to review efficacy and ensure that the most accurate, specific and up-to-date data is published in the name as quickly as possibleText added.
The statement comes after AstraZeneca said Monday that trials on more than 32,000 people in the United States showed that the vaccine was 79% effective in preventing symptoms of COVID-19 in the population and 100% in preventing severe forms of COVID-19. . Illness and hospitalization, as well as making sure that there is no increased risk of blood clots.
File illustration of a vial with the word “vaccine” written in front of the AstraZeneca logo, taken on September 9, 2020. Reuters / Dado Rovich / Clarification / Archive
The AstraZeneca coronavirus vaccine is cheaper and easier to store than others, but several countries temporarily stopped vaccination with this drug last week due to isolated cases of blood clots in some of the people who received it.
The The European Medicines Agency (EMA) has deemed it “safe and effective” The drug has returned to several countries.
However, mistrust still exists, and a YouGov survey, conducted between March 12-18, showed that the majority of respondents in major European countries – including Germany, France, Spain and Italy – do not trust AstraZeneca’s vaccine security.
Before this report was released, Anthony FauciThe leading expert on infectious diseases in the United States government, on Monday, celebrated the results of the nation’s new study of a vaccine against COVID-19 that it developed Oxford / AstraZeneca, That showed a presumed efficacy of 79 percent against symptomatic cases and 100 percent protection against severe cases.
“The good news is that there was a similar efficacy across all races and ages, meaning a very good efficacy, 79.9 percent, in participants 65 years of age or older.“, Fauci said during the White House COVID-19 Response Team briefing.
Read on:
How the system is being implemented by Uruguay to drive an effective COVID-19 vaccination campaign
The European Union indicated that it “does not need” a Sputnik V vaccine to achieve immunity to COVID-19 in July.
AstraZeneca announced its vaccine is 79% effective and does not carry a risk of stroke after trials in the USA.
